Compare GLDD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | IVA |
|---|---|---|
| Founded | 1890 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2007 | N/A |
| Metric | GLDD | IVA |
|---|---|---|
| Price | $17.01 | $5.64 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $17.00 | $16.20 |
| AVG Volume (30 Days) | ★ 1.8M | 490.5K |
| Earning Date | 05-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $7.56 | $751.20 |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.49 | $2.94 |
| 52 Week High | $17.02 | $7.98 |
| Indicator | GLDD | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 48.15 |
| Support Level | $14.60 | $5.04 |
| Resistance Level | N/A | $5.78 |
| Average True Range (ATR) | 0.03 | 0.37 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 80.00 | 76.97 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.